+ Watch BPAX
on My Watchlist
A biopharmaceutical company that licenses and develops hormone therapy products to treat men and women.
Libigel's true value has yet to be publicized. The safety trials have shown to reduce the risk of cardiovascular events in post menopausal women by 70%. Biosante has submitted two patent application as result of these findings. The timing of employee movement between Abbott and Biosante in relation to Libigel's progression through clinical trials, appears very trusting and suggest that Abbott or AbbVie will either partner or buyout Biosante. It should be noted that the buyout price (if it happens) will have no relation to the present market cap of the company.
Biopharma bubble junk. All its its drugs are pretty much complete failures.http://www.cnbc.com/id/46300316
Advanced Quantitative Momentum Arbitrage (AQMA)(black box)
LibiGel, BPAX's product, received a positive safety rating, expect company to make profits. I'm buying!
i got in at .67 and am happy I did. I am hoping for good news on feb. 14th. Trying to decide if I should sell before then?!
Way oversold on panic sell in December. Unintended results showing positive effectivenees ( 75% ) on preventing cardiovascular accidents in women. 90% chance of FDA approval Feb 14th ( possibly sooner ). Huge pipeline inc cancer drugs in late phase. Will shoot up to $5 or $6 ( could hit $10. )
T-gel should receive approval and any update on libigel will send this soaring
run before fda review nov.14,2011
Cell Genesys shareholders got screwed by management. With GVAX back on track BioSante should do well.
Safety study closed, efficacy guaranteed, 4 million off label T scripts, in talks with "many many" potential buyers, 500 million very very conservative price. risk reward here is great.
I believe Libigel will get approved. Its already a 90% garuntee the FDA will approve it, and if they do it will be a sure monopoly since its the only product of its kind out. Not saying it will turn the company into the next Google, but it will definitely benefit the company
female sex stimuli
nanotech with solide technicals
Spec play...Female VIAGRA sounds like a sure thing pending the FDA labyrinth.
just an untoucched market by an FDA approved drug that doctors say they would rather use
Soon $3 or more. Be carefull with bashers! Great product. And safe! Also buy-out candidate.
Nearing the end of Phase III trials which seem to be successful in proving that new drug Libigel is safe. There is a large market for this drug as there are currently no FDA approved treatments for female sexual dysfunction. Stock price should climb in anticipation for NDA and FDA approval.
Drug company with growth possibilities as Boomers age.
It has more potential than most other stocks and at a good price. My money says it is a go, and some extra cash help from the short sellers is a plus.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions